Recruiting studies: Lymphoma B Cell Aggressive Non Hodgkin B Nhl

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
Phase 2 · 1 location(s) · Koo Foundation Sun Yat-Sen Cancer Center · NCT06461182 Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Phase 1/Phase 2 · 34 location(s) · Lyell Immunopharma, Inc. · NCT05826535 Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R)
Phase 2 · 1 location(s) · University of Washington · NCT07097363 A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcita
Phase 2 · 53 location(s) · Hoffmann-La Roche · NCT06806033 MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Phase 2 · 36 location(s) · Ryvu Therapeutics SA · NCT06534437 A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-
Phase 1 · 20 location(s) · Regeneron Pharmaceuticals · NCT05685173 Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT01853631 Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07059741 Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
Phase 2 · 13 location(s) · The Lymphoma Academic Research Organisation · NCT06271057 Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Phase 1/Phase 2 · 2 location(s) · Yazeed Sawalha · NCT06536049 Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Phase 1 · 7 location(s) · AIDS Malignancy Consortium · NCT05077527 Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed
Phase 2 · 6 location(s) · Academic and Community Cancer Research United · NCT06238648 SynKIR-310 for Relapsed/Refractory B-NHL
Phase 1 · 5 location(s) · Verismo Therapeutics · NCT06544265 A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518 The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
Phase 1/Phase 2 · 1 location(s) · Tianjin Medical University General Hospital · NCT06911710 Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive La
Phase 1 · 1 location(s) · University of Washington · NCT04231877 Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
Phase 2/Phase 3 · 1 location(s) · Children's Cancer Group, China · NCT07168980 Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C
Phase 2 · 7 location(s) · Mayo Clinic · NCT06834373 GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06244368

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.